1
|
Lakhal-Littleton S, Cleland JGF. Iron deficiency and supplementation in heart failure. Nat Rev Cardiol 2024; 21:463-486. [PMID: 38326440 DOI: 10.1038/s41569-024-00988-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 01/08/2024] [Indexed: 02/09/2024]
Abstract
Non-anaemic iron deficiency (NAID) is a strategic target in cardiovascular medicine because of its association with a range of adverse effects in various conditions. Endeavours to tackle NAID in heart failure have yielded mixed results, exposing knowledge gaps in how best to define 'iron deficiency' and the handling of iron therapies by the body. To address these gaps, we harness the latest understanding of the mechanisms of iron homeostasis outside the erythron and integrate clinical and preclinical lines of evidence. The emerging picture is that current definitions of iron deficiency do not assimilate the multiple influences at play in patients with heart failure and, consequently, fail to identify those with a truly unmet need for iron. Additionally, current iron supplementation therapies benefit only certain patients with heart failure, reflecting differences in the nature of the unmet need for iron and the modifying effects of anaemia and inflammation on the handling of iron therapies by the body. Building on these insights, we identify untapped opportunities in the management of NAID, including the refinement of current approaches and the development of novel strategies. Lessons learned from NAID in cardiovascular disease could ultimately translate into benefits for patients with other chronic conditions such as chronic kidney disease, chronic obstructive pulmonary disease and cancer.
Collapse
Affiliation(s)
| | - John G F Cleland
- British Heart Foundation Centre of Research Excellence, School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK
| |
Collapse
|
2
|
Jin M, Jiang Y, Zhao Q, Pan Z, Xiao F. Diagnostic value of T2 relaxation time for hepatic iron grading in rat model of fatty and fibrotic liver. PLoS One 2022; 17:e0278574. [PMID: 36469532 PMCID: PMC9721484 DOI: 10.1371/journal.pone.0278574] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2021] [Accepted: 11/20/2022] [Indexed: 12/12/2022] Open
Abstract
The objective of this study was to assess the quantitative diagnostic value of T2 relaxation time for determining liver iron grades in the presence of fat and fibrosis. Sixty Sprague-Dawley (SD) male rats were randomly divided into control (10 rats) and model (50 rats) groups. The model group of coexisting iron, steatosis, and liver fibrosis was induced by intraperitoneal injection of carbon tetrachloride (CCl4) dissolved in edible vegetable oil (40% v/v). The control group received an intraperitoneal injection of 0.9% saline. All rats underwent multi-echo gradient and spin echo (M-GRASE) magnetic resonance imaging, and the T2 relaxation time of the liver was measured. The rats were killed immediately after imaging, and liver specimens were extracted for histological evaluation of steatosis, iron, and fibrosis. The relationship and differences between T2 relaxation time and liver fibrosis stage, as well as the pathological grade of hepatic steatosis, were assessed by Spearman's rank correlation coefficient, non-parametric Mann-Whitney test, and the Kruskal-Wallis test. The area under the receiver operating characteristic curve and interaction analysis were used to quantify the diagnostic performance of T2 relaxation time for detecting different degrees of liver iron grades. Six normal control rats and 34 model rats were included in this study. Fibrosis stages were F0 (n = 6), F1 (n = 6), F2 (n = 8), F3 (n = 10), and F4 (n = 10). Steatosis grades were S0 (n = 5), S1 (n = 8), S2 (n = 12), and S3 (n = 15). Hepatocyte or Kupffer cell iron grades were 0 (n = 7), 1 (n = 9), 2 (n = 12), 3 (n = 10), and 4 (n = 2). The liver fibrosis stages were positively correlated with the iron grades (P < 0.01), and the iron grades and fibrosis stages were negatively correlated with the T2 relaxation time (P < 0.01). The T2 relaxation times exhibited strongly significant differences among rats with different histologically determined iron grades (P < 0.01). Pairwise comparisons between each grade of liver iron indicated significant differences between all iron grades, except between grades 0 and 1, and between grades 1 and 2 (P > 0.05). The T2 relaxation time of the liver had an area under the receiving operating characteristic curve (AUC) of 0.965 (95% CI 0.908-0.100, P < 0.001) for distinguishing rats with a pathological grade of hepatic iron (grade ≥ 1) from those without, an AUC of 0.871 (95% CI 0.757-0.985, P < 0.001) for distinguishing rats with no iron overload (grade ≤ 1) from rats with moderate or severe iron overload (grade ≥ 2), and an AUC of 0.939 (95% CI 0.865-1.000, P < 0.001) for distinguishing rats with no to moderate iron overload (grade ≤ 2) from rats with severe iron overload (grade 3). The interaction of different pathological grades of iron, steatosis, and fibrosis has a negligible influence on the T2 relaxation time (P > 0.05). In conclusion, T2 relaxation time can assess histologically determined liver iron grades, regardless of coexisting liver steatosis or fibrosis; therefore, it is suitable for distinguishing between the presence and absence of iron deposition and it is more accurate for higher iron grading.
Collapse
Affiliation(s)
- Mingli Jin
- Department of Radiology, The Second Affiliated Hospital of Chengdu Medical College, China National Nuclear Corporation 416 Hospital, Cheng du, Sichuan, People’s Republic of China
| | - Yin Jiang
- Department of Radiology, The Second Affiliated Hospital of Chengdu Medical College, China National Nuclear Corporation 416 Hospital, Cheng du, Sichuan, People’s Republic of China
| | - Qi Zhao
- Department of Radiology, The Second Affiliated Hospital of Chengdu Medical College, China National Nuclear Corporation 416 Hospital, Cheng du, Sichuan, People’s Republic of China
| | - Zhihua Pan
- Department of Radiology, The Second Affiliated Hospital of Chengdu Medical College, China National Nuclear Corporation 416 Hospital, Cheng du, Sichuan, People’s Republic of China
- * E-mail:
| | - Fang Xiao
- Department of Radiology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, People’s Republic of China
| |
Collapse
|
3
|
Rostoker G, Lepeytre F, Merzoug M, Griuncelli M, Loridon C, Boulahia G, Cohen Y. Differential Pharmacokinetics of Liver Tropism for Iron Sucrose, Ferric Carboxymaltose, and Iron Isomaltoside: A Clue to Their Safety for Dialysis Patients. Pharmaceutics 2022; 14:pharmaceutics14071408. [PMID: 35890303 PMCID: PMC9323124 DOI: 10.3390/pharmaceutics14071408] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2022] [Revised: 06/29/2022] [Accepted: 07/02/2022] [Indexed: 01/31/2023] Open
Abstract
Anemia is a major complication of end-stage kidney disease (ESKD). Erythropoiesis-stimulating agents and intravenous (IV) iron are the current backbone of anemia treatment in ESKD. Iron overload induced by IV iron is a potential clinical problem in dialysis patients. We compared the pharmacokinetics of liver accumulation of iron sucrose, currently used worldwide, with two third-generation IV irons (ferric carboxymaltose and iron isomaltoside). We hypothesized that better pharmacokinetics of newer irons could improve the safety of anemia management in ESKD. Liver iron concentration (LIC) was analyzed in 54 dialysis patients by magnetic resonance imaging under different modalities of iron therapy. LIC increased significantly in patients treated with 1.2 g or 2.4 g IV iron sucrose (p < 0.001, Wilcoxon test), whereas no significant increase was observed in patients treated with ferric carboxymaltose or iron isomaltoside (p > 0.05, Wilcoxon-test). Absolute differences in LIC reached 25 μmol/g in the 1.2 g iron sucrose group compared with only 5 μmol/g in the 1 g ferric carboxymaltose and 1 g iron isomaltoside groups (p < 0.0001, Kruskal−Wallis test). These results suggest the beneficial consequences of using ferric carboxymaltose or iron isomaltoside on liver structure in ESKD due to their pharmacokinetic ability to minimize iron overload.
Collapse
Affiliation(s)
- Guy Rostoker
- Division of Nephrology and Dialysis, Ramsay Santé, Hôpital Privé Claude Galien, 91480 Quincy-Sous-Sénart, France; (F.L.); (M.M.); (M.G.); (C.L.); (G.B.)
- Collége de Médecine des Hôpitaux de Paris, 75005 Paris, France
- Correspondence: ; Tel.: +33-1-69-39-92-00
| | - Fanny Lepeytre
- Division of Nephrology and Dialysis, Ramsay Santé, Hôpital Privé Claude Galien, 91480 Quincy-Sous-Sénart, France; (F.L.); (M.M.); (M.G.); (C.L.); (G.B.)
| | - Myriam Merzoug
- Division of Nephrology and Dialysis, Ramsay Santé, Hôpital Privé Claude Galien, 91480 Quincy-Sous-Sénart, France; (F.L.); (M.M.); (M.G.); (C.L.); (G.B.)
| | - Mireille Griuncelli
- Division of Nephrology and Dialysis, Ramsay Santé, Hôpital Privé Claude Galien, 91480 Quincy-Sous-Sénart, France; (F.L.); (M.M.); (M.G.); (C.L.); (G.B.)
| | - Christelle Loridon
- Division of Nephrology and Dialysis, Ramsay Santé, Hôpital Privé Claude Galien, 91480 Quincy-Sous-Sénart, France; (F.L.); (M.M.); (M.G.); (C.L.); (G.B.)
| | - Ghada Boulahia
- Division of Nephrology and Dialysis, Ramsay Santé, Hôpital Privé Claude Galien, 91480 Quincy-Sous-Sénart, France; (F.L.); (M.M.); (M.G.); (C.L.); (G.B.)
| | - Yves Cohen
- Division of Radiology, Ramsay Santé, Hôpital Privé Claude Galien, 91480 Quincy-Sous-Sénart, France;
| |
Collapse
|
4
|
Tabasi O, Razlighi MR, Darbandi MA. An Optimized Process for the Preparation of Aqueous Ferric Carboxymaltose: Synthesis and Structural Characterization. Pharm Nanotechnol 2021; 9:157-163. [PMID: 33459254 DOI: 10.2174/2211738509666210114160941] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2020] [Revised: 12/08/2020] [Accepted: 12/18/2020] [Indexed: 11/22/2022]
Abstract
BACKGROUND Ferric carboxymaltose (FCM) formulation consists of iron-carbohydrate nanoparticles where iron-oxyhydroxide as a core is covered by a carbohydrate shell. The present work provides an improved synthesis process of FCM as an intravenous iron, active pharmaceutical ingredient. METHODS Water-soluble FCM complex was prepared from the reaction of ferric hydroxide precipitation with an aqueous solution of oxidized maltodextrin (MD) at optimum temperature and pH conditions. A systematic approach was followed to obtain the optimal weight ratio of the maltodextrin/ ferric chloride for FCM synthesis process with suitable-sized nanoparticles. Physical characterization of newly synthesized ferric carboxymaltose (FCM-NP) was performed to establish its equivalency with the reference product (Ferinject). RESULTS The size distribution of the whole nanoparticles determined by dynamic light scattering (DLS) was in the range of 15-40 nm with an average particle size of 26 ± 6.6 and 25.8 ± 4.9 for FCM-NP and Ferinject, respectively. X-ray diffraction (XRD) results of FCM-NP and Ferinject indicated the Akaganeite structure of iron-oxyhydroxide. The iron content of particles (cores) measured by Atomic absorption spectroscopy (AAS) was almost equal for the two formulations. The Fourier transform infrared (FTIR) spectra of Ferinject and FCM-NP were approximately similar. CONCLUSION Various analytical methods, including FTIR spectroscopy, XRD analysis, DLS technique, TEM, and AAS were employed. It was observed that the specifications of FCM-NP obtained by these analyses were almost identical to those of Ferinject. Accordingly, the two formulations were considered comparable.
Collapse
Affiliation(s)
- Ozra Tabasi
- Research and Development unit, Nafas Zist Pharmed Pharmaceutical Company, Science and Technology Park of Islamic Azad University, Tehran, Iran
| | - Mahdi Roohi Razlighi
- Research and Development unit, Nafas Zist Pharmed Pharmaceutical Company, Science and Technology Park of Islamic Azad University, Tehran, Iran
| | - Mohammad Ali Darbandi
- Research and Development unit, Nafas Zist Pharmed Pharmaceutical Company, Science and Technology Park of Islamic Azad University, Tehran, Iran
| |
Collapse
|
5
|
Tangchitphisut P, Srikaew N, Phongkitkarun S, Jaovisidha S, Tawonsawatruk T. Using iron sucrose-labeled adipose-derived mesenchymal stem cells in 1.5 and 3 T MRI tracking: An in vitro study. Heliyon 2020; 6:e04582. [PMID: 32775748 PMCID: PMC7398940 DOI: 10.1016/j.heliyon.2020.e04582] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2019] [Revised: 01/31/2020] [Accepted: 07/27/2020] [Indexed: 01/04/2023] Open
Abstract
Objectives The objective of this study was to investigate iron sucrose labeling in mesenchymal stem cell (MSCs) tracking. Background Adipose-derived mesenchymal stem cell-based therapy is a promising strategy for promoting musculoskeletal repair. Methods Iron sucrose-labeled adipose-derived mesenchymal stem cells (IS-labeled ASCs) were tracked using T2-and T2∗-weighted sequences by 1.5 and 3 T MRI in an in vitro model. ASCs were isolated from cosmetic liposuction specimens. ASCs from passages 4-6 were labeled with iron sucrose (Venofer®) which was added to the cell culture medium. Pre- and post-iron sucrose labeled ASCs were evaluated for cell surface immunophenotypes. Cell viability as well as chondrogenic, adipogenic and osteogenic differentiation of IS-labeled-ASCs were evaluated. The IS-labeled ASCs were titrated into microtubes at 1 × 103, 1 × 104, 1 × 105 and 1 × 106 cells/ml/microtube and their intensities were determined by 1.5 and 3T MRI using T2-and T2∗-weighted sequences. Results The expression markers of IS-labeled ASCs from flow cytometry were equivalent to control. The mean cell viability was 97.73 ± 2.06%. Cell differentiations of IS-labeled ASCs were confirmed in each lineage using specific staining solutions. T2∗-weighted sequences (T2∗) were able to detect iron sucrose labeled-ASCs at a minimum of 1 × 105 cells/ml/microtube using 1.5 and 3T MRI, but the detection sensitivity was lower with T2-weighted sequences (T2). Conclusions Iron sucrose incubation is a safe alternative method for ASCs labeling and tracking using MRI following treatment. Clinicians and researchers should be able to visualize the location of ASCs engraftment without secondary surgical investigation involving tissue sampling.
Collapse
Affiliation(s)
| | | | - Sith Phongkitkarun
- Department of Radiology, Faculty of Medicine, Ramathibodi Hospital, Thailand
| | | | | |
Collapse
|
6
|
Wu S, Zhang H, Wang J, Li X, Gao X, Fang Z, Qu J, Wu Y, Ren Y, Rui W, Zhang J, Yao Z. Iron Sucrose as MRI Contrast Agent in Ischemic Stroke Model. J Magn Reson Imaging 2020; 52:836-849. [PMID: 32112623 DOI: 10.1002/jmri.27109] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/27/2019] [Revised: 02/13/2020] [Accepted: 02/13/2020] [Indexed: 11/08/2022] Open
Abstract
BACKGROUND Despite the growing concern about the safety of gadolinium-based contrast agents (GBCAs), they are still the most commonly used. Ferumoxytol, as an off-label alternative MRI contrast agent, cannot be administered by a rapid bolus for dynamic susceptibility contrast perfusion-weighted imaging (DSC-PWI). PURPOSE To assess the feasibility of iron sucrose (IS) as a contrast agent for MR angiography (MRA) and DSC-PWI. STUDY TYPE Prospective animal model. ANIMAL MODEL Thirty-six normal rats (16 for MRA, 20 for biocompability tests) and 36 occlusion of the middle cerebral artery (MCAO) model rats. FIELD STRENGTH/SEQUENCE 3.0T; head and neck angiography, using a fast spoiled gradient-recalled-echo (FSPGR) sequence and DSC-MRI using echo planar imaging(EPI) sequence. ASSESSMENT MRA was performed on normal rats to examine the signal-to-noise ratio (SNR) and contrast-to-noise ratio (CNR) of different doses of IS. DSC-PWI was performed on MCAO rats at 0, 24, 48, and 72 hours postreperfusion to investigate the lesion detectability of IS. Arterial spin labeling (ASL) and DSC-PWI enhanced by GBCAs were conducted on MCAO rats as controls. STATISTICAL TESTS Kruskal-Wallis test was used to compare qualitative assessment. One-way analysis of variance (ANOVA) was used to compare the parametric data. Pearson's r values were evaluated between relative cerebral blood flow(rCBF)-ASL, rCBF-DSCIS , and rCBF obtained from DSC-PWI enhanced by GBCA. RESULTS The mean SNR and CNR of the common carotid artery at doses of 10 mg Fe/kg of IS were comparable with the standard dose of GBCAs (SNR: 68.04 ± 12.55 vs. 67.72 ± 14.66; CNR: 23.78 ± 7.21vs. 21.63 ± 6.83). In MCAO rat models, rCBF and relative cerebral blood volume (rCBV) of ipsilateral striatum declined (0.72 ± 0.14, 0.86 ± 0.11) with prolonged relative mean transit time (rMTT) and relative time-to-peak (rTTP) (1.27 ± 0.24, 1.07 ± 0.03) following occlusion. Hyperperfusion was observed in all rats at 48 and 72 hours postreperfusion, in 4/6 rats at 24 hours postreperfusion for IS-mediated DSC-PWI. DATA CONCLUSION IS may be an effective contrast agent for both MRA and DSC-PWI in ischemic stroke models. LEVEL OF EVIDENCE 1 TECHNICAL EFFICACY STAGE: 1 J. Magn. Reson. Imaging 2020;52:836-849.
Collapse
Affiliation(s)
- Shiman Wu
- Department of Radiology, Huashan Hospital, Fudan University, Shanghai, China
| | - Hua Zhang
- Department of Radiology, The Affiliated Hospital of Qingdao University, Qingdao, China
| | - Jing Wang
- Department of Radiology, Huashan Hospital, Fudan University, Shanghai, China
| | - Xiaoyan Li
- Department of General Surgery, Huashan Hospital, Fudan University, Shanghai, China
| | - Xinyi Gao
- Department of Radiology, Zhejiang Cancer Hospital, Hangzhou, China
| | - Ziwei Fang
- Department of Radiology, Huashan Hospital, Fudan University, Shanghai, China
| | - Jianxun Qu
- GE Healthcare, MR research, Applied Science Lab, Shanghai, China
| | - Yue Wu
- Department of Radiology, Huashan Hospital, Fudan University, Shanghai, China
| | - Yan Ren
- Department of Radiology, Huashan Hospital, Fudan University, Shanghai, China
| | - Wenting Rui
- Department of Radiology, Huashan Hospital, Fudan University, Shanghai, China
| | - Junhai Zhang
- Department of Radiology, Huashan Hospital, Fudan University, Shanghai, China
| | - Zhenwei Yao
- Department of Radiology, Huashan Hospital, Fudan University, Shanghai, China
| |
Collapse
|
7
|
Regulatory challenges of nanomedicines and their follow-on versions: A generic or similar approach? Adv Drug Deliv Rev 2018; 131:122-131. [PMID: 29966685 DOI: 10.1016/j.addr.2018.06.024] [Citation(s) in RCA: 65] [Impact Index Per Article: 10.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2018] [Revised: 06/21/2018] [Accepted: 06/26/2018] [Indexed: 12/12/2022]
Abstract
Nanomedicines and follow-on versions (also called nanosimilars in the EU) have been on the market partially for decades although without recognition of their nano properties in the beginning; a substantial number is in clinical development. Nanomedicines are typically synthetic and belong to the non-biological complex drugs. They show a high variability in form, structure, and size. Additionally large molecule biologics show nano-characteristics meaning nano-dimension in size (1-100 nm) or specific properties related to these dimensions. The high complexity of nanomedicines with their heterogeneous structures do not allow a full physicochemical quality characterization, challenging the regulatory evaluation especially for follow-on versions upon comparison with the reference product. The generic paradigm with the sameness approach for quality and bioequivalence in blood plasma is not appropriate for nanomedicines where a similar approach is needed. After experiencing non-equivalence of authorized parenteral colloidal iron follow-on versions, EMA and FDA issued reflection papers and draft guidances for industry to present their current thinking on the evaluation of such complex products. A stepwise approach to evaluate the extent of similarity, from quality, including critical quality attributes (CQA) and assessment of nano properties, to a non-clinical biodistribution assay, required in the the EU but not in the US, and to clinical evaluation makes sense. The cumulated totality of evidence for the authorization of nanomedicine follow-on versions goes case-by-case. Interchangeability, or substitutability, is a challenge. However, a defined or even harmonized approval pathway for these follow-versions is still missing and causes potential differences in approval. To progress, a science-based discussion platform among stakeholders and experts in the field is necessary. An agenda has been agreed [5], namely CQA assessment, publication of scientific and clinical findings, consensus on nomenclature and labelling, and regulatory actions on substandard complex drug products. Consensus created in a public private approach will support progress towards a defined and harmonized regulatory pathway for nanomedicines and their follow-on versions. This will provide drug innovation but also larger access to follow-on versions of nanomedicines, both a benefit for the patient.
Collapse
|